FINHUB Insights

SYK · Q3 FY24 · Jul 1 – Sep 30, 2024

Stryker Q3 FY24: where the revenue came from and where it went

Stryker Q3 FY24: revenue $5.5B (+12% year over year). Net profit $0.8B. Largest cohort Med Surg and Neurotechnology $3.2B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2024
Reported
Oct 30, 2024 10-Q
Sankey diagram of Stryker's income statement for Q3 FY24: revenue of $5.5 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$5.5B +12% year over year
Gross profit$3.5B 64% margin
Operating profit$1.1B 20% margin
Net profit$0.8B 15% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY24 (period ends Sep 30, 2024).
ItemValueShare of revenueYear over year
Revenue 5.5 100% +12%
Med Surg and Neurotechnology 3.2 58% +13%
Orthopaedics and Spine 2.3 42% +11%
Cost of revenue−236%
Gross profit3.564% margin+0pp
Research & development−0.47%+0pp
SG&A−1.834%+0pp
Other−0.23%+0pp
Operating profit1.120% margin+1pp
Tax−0.3
Net profit0.815%+1pp
Filing on EDGAR More quarters of SYK

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters